Crager, Michael
Wijayawardana, Sameera R.
Gruver, Aaron M.
Blacklock, Andrea
Russell, Christy
Baehner, Frederick L.
Sapunar, Francisco
Article History
Received: 28 June 2022
Accepted: 26 October 2022
First Online: 1 November 2022
Declarations
:
: The WCG IRB reviewed and approved the study protocol and found that this research met the requirements for a waiver of consent under 45 CFR 46 116(f) [2018 Requirements] 45 CFR 46.116(d) [Pre-2018 Requirements]. This study was conducted in accordance with the Declaration of Helsinki.
: This manuscript does not include any individual person’s details, so patient consent for publication is not applicable in this case. All authors listed approved the present manuscript and consented for its publication.
: Michael Crager reports being an employee and owning stock or stock options and receiving support for attending meetings and/or travel from Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. Sameera R. Wijayawardana reports being an employee and owning stock or stock options at Eli Lilly and Company. Aaron M. Gruver reports being an employee and owning stock or stock options at Eli Lilly and Company; he also reports being a contributor to a pending patent application for immunohistochemistry (IHC) protocols and methods for diagnosing and treating cancer with Agilent Technologies, Inc. and Eli Lilly and Company listed as the patent applicants. Andrea Blacklock reports being an employee and owning stock or stock options at Exact Sciences. Christy Russell reports being an employee and owning stock or stock options at Exact Sciences. Frederick Baehner reports being an employee and owning stock or stock options at Exact Sciences. Francisco Sapunar reports being an employee and owning stock or stock options at Eli Lilly and Company.